What is Bionano Genomics Inc. (BNGO) Price Targets?

0
11
BEPC Stock
BEPC Stock

Bionano Genomics Inc. (NASDAQ:BNGO) saw an upside of 4.92% to close Monday at $1.92 after adding $0.09 on the day. The 5-day average trading volume is 7,306,460 shares of the company’s common stock. It has gained $1.9800 in the past week and touched a new high 2 times within the past 5 days. An average of 6,317,490 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 7,582,616.

BNGO’s 1-month performance is 16.36% or $0.4000 on its low of $1.3650 reached on 12/27/22. The company’s shares have touched a 52-week low of $1.16 and high of $4.35, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, BNGO has achieved 31.51% or $0.4600 and has reached a new high 7 times. However, the current price is down -55.86% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Insider Transactions

BNGO stock investors last saw insider trading activity on Aug 15.Linney Yvonne (Director) most recently sold 20,000 shares at $3.62 per share on Aug 15. This transaction cost the insider $72,402.

Valuation Metrics

BNGO stock has a beta of 2.26. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 20.45 while the price-to-book (PB) in the most recent quarter is 1.98.

Bionano Genomics Inc.’s quick ratio for the period ended June 29 was 5.80, with the current ratio over the same period at 6.50. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.01, while the total debt to equity was 0.01. In terms of profitability, the gross margin trailing 12 months is 16.90%. The firm’s gross profit as reported stood at $3.87 million against revenue of $17.98 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Bionano Genomics Inc.’s cash and short-term investments amounted to $152.02 million against total debt of $10.76 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 34.77% to -$31.81 million, while revenue of -$32.16 million was -1.1% off the previous quarter. Analysts expected BNGO to announce -$0.09 per share in earnings in its latest quarter, but it posted -$0.11, representing a -22.20% surprise. EBITDA for the quarter stood at more than -$29.57 million. BNGO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 41.96 million, with total debt at $10.76 million. Shareholders hold equity totaling $296.93 million.

Let’s look briefly at Bionano Genomics Inc. (BNGO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 62.40% to suggest the stock is trending Neutral, with historical volatility in this time period at 87.61%.

The stock’s 5-day moving average is $1.8460, reflecting a +6.08% or $0.1100 change from its current price. BNGO is currently trading +19.25% above its 20-day SMA, -21.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -15.79% and SMA200 by-25.87%.

Stochastic %K and %D was 73.22% and 72.49% and the average true range (ATR) pointed at 0.1389. The RSI (14) points at 56.89%, while the 14-day stochastic is at 90.16% with the period’s ATR at 0.1418. The stock’s 9-day MACD Oscillator is pointing at 0.0044 and 0.1224 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Bionano Genomics Inc. (NASDAQ: BNGO), Scotiabank launched coverage with a Sector outperform rating. Analysts offering their rating for BNGO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BNGO as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.

What is BNGO’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $3.50 and a high of $12.00, with their median price target at $6.00. Looking at these predictions, the average price target given by analysts is for Bionano Genomics Inc. (BNGO) stock is $6.70.

LEAVE A REPLY

Please enter your comment!
Please enter your name here